Is there a generic version of Ozempic anywhere?

Yes, in Canada. Health Canada authorized Dr. Reddy's generic semaglutide injection on April 28, 2026, the first generic semaglutide approved in a G7 country, followed by Apotex on May 1, 2026 [1][2].

Why did Canada get generics before the United States?

Novo Nordisk's Canadian patent on acylated GLP-1 compounds lapsed after a missed maintenance fee, and Canadian data protection expired on January 4, 2026. US exclusivity runs to 2032 and EU exclusivity to 2031 [3][4][5].

Where is the Wegovy pill available?

As of mid-2026 the oral semaglutide 25 mg tablet had been approved in the United States, the United Kingdom, the United Arab Emirates, Bahrain and the European Union [7][8][9].

Do all countries warn about the same semaglutide side effects?

No. European regulators added sudden vision loss (NAION) to semaglutide product information in June 2025 and the UK did so in February 2026. The US label did not carry a NAION warning as of September 14, 2026 [10][11][12].

Is Wegovy approved in Australia?

Yes. It entered the Australian Register of Therapeutic Goods on September 1, 2022, though it did not reach Australian pharmacies until August 2024. A cardiovascular indication was added in December 2024 [13][14].

Can I import semaglutide from another country?

Personal importation of prescription drugs into the United States is generally not permitted, and FDA has warned about counterfeit and illegally sold GLP-1 products entering the supply chain. Any sourcing question should go to a licensed pharmacist or prescriber [12].

Semaglutide Approvals by Country: Where Ozempic and Wegovy Are Approved

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Semaglutide is approved in around 100 countries, but the details differ more than most people expect. The same molecule can be a diabetes-only drug in one country and an obesity drug in another. One regulator warns about a side effect that another does not. And in 2026, one country got generic versions years before the rest of the world.

This guide walks through the major markets, the dates, and the places where the rules genuinely diverge. It is reference information, not medical advice, and it is written for a US reader who wants to understand how the American picture compares.

United States: the reference market

The FDA approved Ozempic on December 5, 2017, Rybelsus on September 20, 2019 and Wegovy on June 4, 2021. Since then the US label has expanded further than almost anywhere else:

Cardiovascular risk reduction in type 2 diabetes (January 2020)
Adolescents aged 12 and older for weight management (December 2022)
Cardiovascular risk reduction in obesity or overweight (March 2024)
Chronic kidney disease in type 2 diabetes (January 2025)
Noncirrhotic MASH with F2 to F3 fibrosis, under accelerated approval (August 2025)
Cardiovascular risk reduction with oral semaglutide (October 2025)
The Wegovy pill, oral semaglutide 25 mg (December 2025)
Wegovy HD 7.2 mg (March 2026)

The US also holds exclusivity longest. Reporting at the time of the Chinese Wegovy approval put Novo Nordisk’s US exclusivity through 2032 and its European exclusivity through 2031 [5]. That is why there is no generic Ozempic in an American pharmacy, and will not be for years.

European Union: early approvals, different warnings

The European Commission granted an EU-wide marketing authorization for Ozempic on February 8, 2018 [6] and for Wegovy on January 6, 2022 [15]. Both authorizations cover all EU member states at once, which is the main structural difference from the United States.

Recent EU actions:

December 2024: kidney disease progression data added to the Ozempic product information, roughly six weeks ahead of the equivalent US approval.
June 6, 2025: the EMA’s Pharmacovigilance Risk Assessment Committee concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people, and ordered it added to the Ozempic, Rybelsus and Wegovy product information [10].
February 17, 2026: the European Commission approved Wegovy 7.2 mg, following a CHMP positive opinion on December 12, 2025 [22].
July 15, 2026: the European Commission approved the Wegovy pill and a ready-to-use single-dose 7.2 mg pen, after a CHMP opinion on May 21, 2026 [9].

The EU label also carries clinical data the US label does not, including information on heart failure with preserved ejection fraction symptoms and knee osteoarthritis pain [22].

United Kingdom: first in Europe with the pill

The MHRA has moved quickly since Brexit gave it an independent approval route:

January 2026: approval of the higher 7.2 mg Wegovy dose, reported by UK sources based on the STEP UP results.
February 5, 2026: UK product information updated for the very rare risk of NAION across Wegovy, Ozempic and Rybelsus [11].
June 11, 2026: authorization of the semaglutide (Wegovy) tablet for adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition. It made the UK the first country in Europe to license an oral GLP-1 specifically for weight management [7]. The UK dosing schedule starts at 1.5 mg daily and steps up through 4 mg, 9 mg and 25 mg with a minimum of one month at each level.
July 3, 2026: a new indication covering metabolic dysfunction-associated steatohepatitis.

Canada: the first generics in the G7

This is the most consequential international story of 2026.

Novo Nordisk’s Canadian patent CA 2601784, covering acylated GLP-1 compounds, is recorded as expired. The Canadian Patents Database shows the last maintenance fee was received in October 2018 and the window to reverse the lapse closed in August 2020 [3]. Canada’s certificate of supplementary protection register lists a March 20, 2026 expiry date with a term that would otherwise have extended to March 20, 2028 [3]. Data protection expired on January 4, 2026 [4].

The result:

Date	Action
April 28, 2026	Health Canada authorizes Dr. Reddy’s generic semaglutide injection for type 2 diabetes, the first generic semaglutide approved in the G7 [1]
May 1, 2026	Apotex’s Apo-Semaglutide Injection authorized; launched commercially May 14, 2026 [2]
May 15, 2026	Dr. Reddy’s product reaches Canadian pharmacies [2]
June 29, 2026	Health Canada approves Apotex’s Sevmia, a generic of Wegovy for chronic weight management in people aged 12 and older, with six more generic submissions still under review [20]

Canada is described by Sandoz as the world’s second largest semaglutide market, and Canadian generics are typically 45% to 90% cheaper than brand products [4]. None of that changes US availability. Personal importation of prescription drugs into the United States is generally not permitted, and the FDA has spent the past two years warning about counterfeit and illegally sold GLP-1 products in the supply chain [12].

Australia: registered early, available late

Wegovy entered the Australian Register of Therapeutic Goods on September 1, 2022, but did not actually reach Australian pharmacies until August 2024 [13]. That two-year gap is a useful reminder that regulatory approval and market availability are different things.

Other Australian milestones:

Adolescent indication decided January 3, 2024, entered on the ARTG February 29, 2024 [13]
Cardiovascular risk reduction indication approved December 2024 [14]
A Wegovy 2.4 mg prefilled syringe presentation added to the ARTG March 3, 2026
July 23, 2026: the TGA issued a class-wide medicines safety update and added NAION to the Product Information for every GLP-1 receptor agonist sold in Australia, including Ozempic, Wegovy, Mounjaro, Saxenda and Trulicity, after 36 reported Australian cases [23][24]

Australia also ran a long Ozempic shortage. The TGA advised prescribers not to start new patients during the 2022 to 2023 crunch, and supply stayed constrained into 2025. The 1.5 mL Ozempic 0.25/0.5 mg pen was deleted from the market on December 31, 2025 and replaced by a 3 mL presentation.

Japan: approved, but narrowly

Japan approved Ozempic subcutaneous injection in March 2018 and Rybelsus tablets in June 2020 for type 2 diabetes [16].

Wegovy followed in March 2023 under an indication that is noticeably tighter than the US one. Japanese approval covers obesity disease, but is limited to patients who also have hypertension, dyslipidemia or type 2 diabetes and who meet Japanese BMI thresholds [17]. Japan generally uses lower BMI cut-offs for obesity than the United States, reflecting different body composition and cardiometabolic risk at a given BMI.

On June 19, 2026, Japan’s Ministry of Health, Labour and Welfare granted a partial change approval adding noncirrhotic MASH with moderate to advanced fibrosis, based on the ESSENCE study [18].

China: approved, then a patent cliff

Ozempic was approved in China in 2021. On June 25, 2024 the National Medical Products Administration approved Wegovy for long-term weight management in adults with a BMI of 30 or higher, or 27 to 30 with at least one weight-related risk factor [5].

On September 10, 2026 the NMPA approved Wegovy (semaglutide injection) for metabolic dysfunction-associated steatohepatitis in non-cirrhotic adults with F2 to F3 fibrosis, making it the first and only GLP-1 receptor agonist approved for MASH in China. Novo Nordisk disclosed no launch date, price or reimbursement plan [26][27]. (updated 2026-09-14)

China is where semaglutide’s patent protection ended first among large markets. After a long invalidity fight, the Supreme People’s Court upheld the patent on December 31, 2025, which meant it ran to its scheduled expiry on March 20, 2026 [19]. By the end of 2025, marketing applications for semaglutide copies from at least ten Chinese companies had been accepted by the NMPA, with roughly twenty more in clinical stages.

India, the Gulf and elsewhere

India saw a Wegovy launch in June 2025, and its regulator extended the approval to adolescents in May 2026 [21].

The United Arab Emirates became the first country outside the United States to have the Wegovy pill on sale. The Emirates Drug Establishment approved oral semaglutide 25 mg and Novo Nordisk launched it on June 3, 2026 [8]. By the time of the EU approval in July 2026, the pill had been cleared in the United States, United Kingdom, UAE, Bahrain and the European Union [9].

Where do the labels actually disagree?

The clearest divergence is sudden vision loss.

Europe added NAION to semaglutide product information in June 2025 as a very rare side effect, with the EMA noting that several large epidemiological studies suggest roughly a two-fold increase in risk in adults with type 2 diabetes [10]. The UK followed in February 2026 [11]. Australia followed on July 23, 2026, adding NAION class-wide to GLP-1 Product Information [23][24]. Health Canada is reported to have updated the Ozempic and Mounjaro product monographs on June 23, 2026, although that date comes from a plaintiff law firm announcement rather than a Health Canada page and is not independently confirmed [25].

The United States has not. The current FDA-approved prescribing information for Wegovy injection and tablets does not list NAION in its Warnings and Precautions [12]. That gap is a central allegation in the federal GLP-1 vision loss litigation consolidated as MDL 3163 in the Eastern District of Pennsylvania.

A second divergence runs the other way. In January 2026 the FDA asked manufacturers to remove the suicidal behavior and ideation warning from Saxenda, Wegovy and Zepbound after a meta-analysis of 91 placebo-controlled trials covering 107,910 patients found no increased risk. The Wegovy label records the removal as effective 01/2026 [12].

Regulators look at the same data and sometimes reach different conclusions about what belongs on a label. If you see a warning quoted online, it is worth checking which country’s label it comes from.

Quick reference table

Country or region	Ozempic	Wegovy injection	Oral semaglutide for weight
United States	Dec 5, 2017	Jun 4, 2021	Dec 22, 2025
European Union	Feb 8, 2018	Jan 6, 2022	Jul 15, 2026
Japan	Mar 2018	Mar 2023 (narrow indication)	Not approved as of Sep 2026
Australia	Registered before Wegovy	ARTG Sep 1, 2022, marketed Aug 2024	Not approved as of Sep 2026
China	2021	Jun 25, 2024	Not approved as of Sep 2026
United Kingdom	Pre-Brexit EU authorization carried over	Available privately and via NHS criteria	Jun 11, 2026
UAE	Approved	Approved	Approved, launched Jun 3, 2026
Canada	Approved; generics from Apr 2026	Approved; generic Sevmia Jun 29, 2026	Not approved as of Sep 2026

Dates are approval or registration dates, not launch dates. The two can be years apart, as Australia showed.

What this means if you are in the United States

Three practical takeaways:

Generic semaglutide is not coming to a US pharmacy soon. US exclusivity reportedly runs to 2032 [5]. Anything sold online as “generic Ozempic” in the United States today is not an FDA-approved generic.
Foreign approval is not a safety endorsement for a product you buy online. A product approved in another country and shipped to you is not the product the FDA reviewed, and it may not be the product it claims to be.
Label differences are real and worth asking about. The NAION warning now appears in the EU, UK, Australian and (as reported) Canadian labeling but not the US one. If that concerns you, it is a legitimate topic to raise with your eye doctor or prescriber, even though it is not in the US label.

Sources

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.